Johnson & Johnson is assuming full responsibility for the manufacturing of a drug substance for its Covid-19 vaccine at Emergent BioSolutions Inc.’s Bayview facility, the company said in a statement.

It will add dedicated leaders for operations and quality, and “significantly” increase the number of manufacturing, quality and technical operations personnel at the site, according to the statement.

• Raymond Jumps 4% on Ex-BEL Chief’s Defence Appointment
• Supriya Lifescience Falls 12% on NDPS Act Proceedings
• Radico Hits Record High as Magic Moments Sales Soar 43%
• GK Energy Rallies on Rs 235.92 Crore Solar Pump Order
• Cupid Hits Fresh 52-Week High on Rs 128 Crore Block Deal

The company will work closely with the Food and Drug Administration for the emergency use authorization of the specific facility, adding that all its doses so far have met regulatory quality standards. The company said it expects to deliver almost 100 million doses of the Covid-19 vaccine to the US government by the end of May.